Description

GoodRx’s Pharma Direct Surge: Can 82% Growth Offset Rx Marketplace Pressure?

GoodRx reported its financial results for the first quarter of 2026, showing mixed performance across its business segments with growth in some areas offsetting declines in others. The company recorded total revenue of $194 million and an adjusted EBITDA of $58.3 million, translating into a 30% margin. While prescription transaction revenue declined by 24% year-over-year to $113.7 million, monthly active consumers remained flat sequentially at approximately 5.3 million. This stabilization follows previous declines attributed to factors such as the Rite Aid store closures and changes in integrated savings program volumes. A key growth driver for GoodRx was its Pharma Direct segment, which saw substantial year-over-year revenue growth of 82% to $52.2 million. This growth was driven largely by expansion of manufacturer-sponsored pricing programs and favorable momentum in access to GLP-1 therapies, including recent launches such as the Wegovy pill.